ELV
T3Elevance Health Inc.
AI '25: Data OwnersBS Jobs '26: Call Center SprawlData Owners '25: Healthcare, Claims & Clinical Data
OverviewElevance Health Inc. (ELV) is a leading health benefits organization, guiding approximately 44.9 million members with medical, digital, pharmacy, and behavioral
Elevance Health Inc. (ELV) is a leading health benefits organization, guiding approximately 44.9 million members with medical, digital, pharmacy, and behavioral health solutions. It operates through Health Benefits (Commercial, Medicare, Medicaid, Individual ACA) and Carelon, which provides integrated health services. Elevance Health leverages AI to enhance care management, improve member experience, and drive operational efficiency across its diverse portfolio.
- What They Do (Plain English & Analogies)
- Elevance Health is like a health navigator and partner for millions of people. They offer various health plans (medical, dental, vision, pharmacy, behavioral health) to individuals, families, employers, and government programs like Medicare and Medicaid. Beyond just insurance, they also provide a range of healthcare services, using technology and data to help people manage their health, find care, and make healthcare simpler and more affordable. Think of them as a comprehensive health ecosystem, not just a company that pays medical bills, but one that actively helps you stay healthy and get the right care when you need it, from managing chronic conditions to navigating complex treatments.
- Very Brief History
- Founded in 1944, the company operated for many years as Anthem, Inc. In June 2022, it rebranded to Elevance Health Inc., reflecting its expanded focus on providing holistic health and wellness solutions beyond traditional health insurance. This evolution aimed to streamline its brand portfolio and emphasize its role as a lifetime trusted health partner.
- "Street Stereotype"
- Elevance Health is generally perceived by investors and analysts as a large, diversified managed care organization with a significant presence in government-sponsored programs (Medicaid and Medicare Advantage) and commercial health benefits. It's seen as a company that is actively working to transform into a broader 'whole health' company, leveraging its scale and data to manage healthcare costs and improve member experiences, particularly through its Carelon services arm and AI-enabled capabilities. However, it also faces scrutiny regarding the profitability and stability of its Medicaid business due to dynamic operating environments.
- Subsidiaries On Linked In*
- Carelon — Healthcare services brand, consolidates various capabilities like pharmacy, behavioral health, and care delivery.; LinkedIn: carelon
- CarelonRx — Pharmacy benefit management (PBM) services under the Carelon umbrella.; LinkedIn: carelonrx
- Carelon Services — Broader care delivery and healthcare enablement capabilities under Carelon.; LinkedIn: carelon-services
- Wellpoint — Unifies Medicare, Medicaid, and Commercial health plans in select markets, formerly Amerigroup.; LinkedIn: wellpoint
- Anthem Blue Cross — Health plan brand in California.; LinkedIn: anthem-blue-cross
- Anthem Blue Cross and Blue Shield — Health plan brand in 14 states.; LinkedIn: anthem-blue-cross-and-blue-shield
- Carelon Global Solutions — Business Process Outsourcing/Shared Services subsidiary of Carelon.; LinkedIn: carelon-global-solutions
- Amerigroup — Formerly a brand for Medicaid plans, now largely unified under Wellpoint.; LinkedIn: amerigroup
- UniCare — Health plan brand in certain markets, e.g., West Virginia.; LinkedIn: unicare
- National Government Services — Government contractor for Medicare and other federal programs.; LinkedIn: national-government-services
- Customer Sectors & Example Clients
- Elevance Health serves a diverse range of customer sectors. These include: **Government:** Federal and state governments for their Medicare Advantage (for seniors and dual-eligible members) and Medicaid programs. **Employers:** Large and small employer groups, including national accounts, offering health benefits to their employees. **Individuals:** People purchasing health coverage directly, often through the Affordable Care Act (ACA) marketplaces. As a health benefits organization, their direct 'clients' are often the members themselves, employers, or government agencies. Specific employer clients are typically not publicly disclosed due to competitive reasons. However, the transcript mentions "employers" as a key customer group, and the company's Blue Cross Blue Shield plans serve millions of individuals.
- New Customers / Segments They'Re Targeting
- Elevance Health is actively targeting several new customer sets and expanding into specific segments. They are focusing on **dual-eligible members** within Medicare Advantage, emphasizing plans where they can deliver sustainable value. Through their Carelon segment, they are scaling value-based solutions to address complex and fast-growing areas of healthcare spend, expanding these capabilities to **new populations and external client relationships**. This includes extending Carelon's 'whole health' model into the home with solutions like CareBridge and focusing on areas like behavioral health and oncology. They are also looking to grow their Medicare Advantage portfolio by 7-9% in 2025.
- Supply Chain And Sourcing Geographies
- Elevance Health's 'supply chain' is primarily service-oriented, rather than involving the sourcing of physical products from specific geographies. It encompasses a vast network of healthcare providers, including hospitals, physicians, pharmacies, and other clinical service providers, predominantly located across the **United States** where their members reside and receive care. Additionally, their supply chain involves partnerships with technology vendors for digital platforms and AI capabilities, as well as administrative service providers. The company emphasizes supply chain sustainability, requiring suppliers to align with ESG standards, comply with environmental regulations, and minimize harm to human health, indicating a focus on responsible practices within their service-based value chain.
- Sales Geographies And Expansion Plans
- Elevance Health primarily sells its health plans and services across the **United States**. They operate Blue Cross Blue Shield plans in 14 states (California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia, and Wisconsin). They also have a national reach through their large employer accounts, government programs (Medicare and Medicaid), and Carelon services. Regarding expansion plans, the company recently reached a mutual agreement to exit the **District of Columbia Medicaid market** and expects to exit **additional Medicaid markets over the next 12-18 months** where they do not see a path to sustainable performance. Despite these exits, they remain committed to serving Medicaid members in markets where they can deliver value. In 2023, Elevance announced an agreement to acquire Blue Cross and Blue Shield of Louisiana, which would increase their footprint to 15 states and add 1.9 million new members.
- How Key Themes May Help/Hurt
- Elevance Health is well-positioned to benefit significantly from the 'AI '25: Data Owners' theme. As a large health benefits organization, it possesses vast amounts of proprietary claims, clinical, and member interaction data, which is a critical asset in the second phase of AI value creation. The integration of AI into its operations, as highlighted by its investments in AI-enabled capabilities like Sydney Health, Concierge Care, and Health OS, can lead to earlier detection of medical cost trends, more precise clinical interventions, a simpler member experience, and better provider connectivity. These AI-driven improvements are expected to enhance operational efficiency, drive margin improvement, and create defensible data moats by continuously improving its products and services. The company's focus on agentic use cases, where AI systems operate autonomously within existing workflows (e.g., for medical cost management and provider connectivity), aligns directly with the theme's emphasis on tangible productivity gains and ROI. Conversely, potential 'bear' aspects of the AI theme could hurt Elevance Health if not managed effectively. These include the slow pace of behavioral change among people and existing processes, which could bottleneck AI adoption and delay the realization of ROI. Additionally, the complex and fragmented regulatory landscape concerning data privacy, security, and algorithmic accountability (e.g., EU AI Act, US state AI laws) poses compliance challenges and legal risks. While Elevance Health's proprietary data is a strength, the increasing commoditization of foundational AI models could erode differentiation if the company doesn't effectively translate its data advantage into unique, hard-to-replicate product experiences.
3 Main Long-Term Bull Details
- Diversified Portfolio and Strategic Investments: Elevance Health's broad portfolio across Commercial, Medicare Advantage, Individual ACA, and Carelon, coupled with targeted, non-recurring investments in AI-enabled capabilities for medical cost management, member engagement, and provider connectivity, is expected to drive long-term durable performance and a return to at least 12% adjusted EPS growth in 2027.
- Scaling Carelon's Value-Based Solutions: The continued scaling of Carelon's solutions, particularly in complex and chronic care areas like behavioral health, CareBridge (home-based care), and oncology, represents a significant and durable driver of enterprise growth by improving outcomes and lowering costs for members and external clients.
- Disciplined Execution and Market Positioning: The company's disciplined plan design and focused product mix in Medicare Advantage are translating into stronger performance and sustainable margins. Similarly, disciplined pricing and strong demand for integrated medical and pharmacy offerings in the Commercial segment, along with prudent management of the Individual ACA business, position Elevance Health for consistent performance across its health benefits segments.
3 Main Long-Term Bear Details
- Dynamic Medicaid Environment and Market Exits: The Medicaid business continues to face a dynamic operating environment with elevated cost trends. While the company is taking actions, it expects to exit additional Medicaid markets over the next 12-18 months where sustainable performance cannot be achieved, indicating ongoing challenges and potential revenue/membership attrition in this segment.
- Persistent Elevated Utilization Trends: Despite management's actions, elevated utilization, particularly in categories like behavioral health, specialty pharmacy, outpatient surgery, and emergency department utilization, remains a persistent cost driver across various lines of business, posing a continuous challenge to medical cost management.
- Regulatory and Acuity Pressures: While the company views upcoming regulatory changes like the One Big Beautiful Bill Act (OBBBA) and work requirements as manageable, they still introduce incremental acuity pressure and operational complexities. The need for ongoing prudence in outlooks reflects the inherent volatility and regulatory sensitivity of the healthcare industry.
- Competitors And Differentiation
- Elevance Health operates in a highly competitive market, with its main competitors being other large national health insurers and healthcare service providers. Key competitors include **UnitedHealth Group (UNH), CVS Health (Aetna), The Cigna Group (CI), Humana (HUM), Centene (CNC), Molina Healthcare (MOH), and Kaiser Permanente**. Elevance Health differentiates itself through several key strategies: * **Integrated Medical and Pharmacy Model:** Their integrated approach, particularly with CarelonRx, resonates with employers looking for solutions that lower healthcare costs and simplify navigation. * **Carelon's Value-Based Solutions:** The company is focused on scaling solutions through Carelon that improve outcomes for members with complex and chronic needs, including behavioral health, CareBridge (home-based care), and oncology. * **Digital and AI Innovation:** Elevance Health is accelerating investments in capabilities like Sydney Health, Concierge Care, and Health OS, which use data, digital tools, and AI to improve medical cost trend detection, enhance member experience, and reduce administrative friction for providers. * **Blue Cross Blue Shield Brand:** They leverage their exclusive right to market products under the highly recognized Blue Cross and Blue Shield brand in 14 states, providing strong local market positioning.
- Recent Performance & What The Market'S Focused On
- Elevance Health delivered strong second-quarter 2026 results, exceeding its outlook with adjusted diluted earnings per share of $7.45. This performance was driven by favorable benefit expense in Medicare Advantage and Individual ACA, disciplined expense management, and progress in care management initiatives. The company raised its full-year 2026 adjusted diluted EPS guidance to at least $27. The market is focused on several key areas: the continued dynamic operating environment and targeted market exits in Medicaid, the sustained improvement and disciplined bidding in Medicare Advantage, and the performance of the Individual ACA business, particularly regarding seasonality and risk adjustment. Investors are also closely watching the impact and return on investment from the company's accelerated one-time investments in AI-enabled capabilities and Carelon's integrated solutions, which are intended to strengthen long-term performance and drive the projected 12% adjusted EPS growth in 2027.
- Revenue Segments And Estimated Mix
- Health Benefits (Commercial, Medicare, Medicaid, Individual ACA) — Mix: Largest segment, approximately 90% of revenue in 2025; Source: FY2025 data, Q2 2026 transcript indicates higher premium yields in Health Benefits segment partly offset by lower membership.; Trend: Operating gain in Health Benefits segment collapsed 42.6% year-over-year in Q2 2026, though overall operating revenue increased 0.8% driven by higher premium yields and CarelonRx growth.
- CarelonRx — Mix: Growing contributor, part of the Carelon segment; Source: Q2 2026 transcript mentions growth in CarelonRx product revenue.; Trend: Pleased with early progress in 2027 selling season, reflecting demand for integrated medical and pharmacy offering.
- Carelon Services — Mix: Growing contributor, part of the Carelon segment; Source: Q2 2026 transcript mentions ongoing investment in the platform and scaling of newer risk-based programs.; Trend: Near-term earnings reflect ongoing investment and scaling, which naturally takes time to mature.
- Product Brands
- Anthem Blue Cross
- Anthem Blue Cross and Blue Shield
- Wellpoint
- Carelon
- CarelonRx
- Carelon Services
- CareBridge
- Sydney Health
- Concierge Care
- Health OS
- Carelon Behavioral Health
- Carelon Health
Bull / Bear DetailsElevance Health is a compelling "AI '25: Data Owners" play, leveraging its vast proprietary healthcare data to drive efficiency and enhance member experience. S
Thesis
Elevance Health is a compelling "AI '25: Data Owners" play, leveraging its vast proprietary healthcare data to drive efficiency and enhance member experience. Strategic investments in AI-enabled tools for medical cost management, clinical intervention, and Carelon's growth underpin a strong financial outlook. Despite Medicaid volatility, a diversified portfolio and disciplined execution support confidence in long-term adjusted EPS growth. (2026-07-16)
Bull case
Elevance Health is accelerating investments in AI-enabled capabilities for earlier medical cost trend detection, precise clinical intervention, and improved provider connectivity. These one-time investments, funded by a non-recurring benefit, are designed to strengthen long-term performance and operational efficiency, directly leveraging its proprietary data to drive tangible productivity gains and margin enhancement, aligning with the "AI '25: Data Owners" thesis.
The company's diversified portfolio is demonstrating strong performance, with Medicare Advantage showing clear evidence of improved results due to deliberate repositioning actions. The integrated medical and pharmacy model in the Commercial segment is resonating, leading to strong demand and client win-backs. Carelon and its AI-enabled solutions are also becoming increasingly meaningful contributors, driving enterprise growth and value-based care.
Elevance Health has raised its 2026 adjusted diluted EPS guidance to at least $27 and remains confident in achieving at least 12% adjusted EPS growth in 2027 off a higher baseline. This financial strength is supported by disciplined execution, effective capital deployment, and the expectation that 2026 will be the trough year for Medicaid margins, with improvements anticipated.
Bear case
The Medicaid environment remains dynamic, with elevated cost drivers in behavioral health, specialty pharmacy, outpatient surgery, and emergency department utilization. Elevance Health expects to exit additional Medicaid markets over the next 12-18 months where sustainable performance is not achievable, indicating ongoing challenges and potential membership attrition in this segment, despite some favorable rate updates.
Underlying medical cost trend continues to outpace program funding across the industry, particularly in Medicare Advantage, necessitating a prudent view on future pricing and profitability. While Elevance Health is taking actions, the persistent pressure from elevated utilization, as noted in Medicaid, suggests a challenging environment for managing healthcare costs effectively across all lines of business.
The Individual ACA market is still developing, with a meaningful shift towards bronze plans impacting premium yield and risk adjustment, requiring continued prudence and careful management. Furthermore, the broader "AI '25: Data Owners" theme faces risks from human and organizational inertia in adopting agentic AI, and increasing regulatory complexity around data privacy and algorithmic accountability could slow deployment and increase compliance costs.
Bull / Bear Case
- Bear Case
- The Medicaid environment remains highly dynamic and challenging, with an expected operating margin of approximately -1.75% for 2026, which management views as a trough year. Elevance Health plans to exit additional Medicaid markets over the next 12-18 months due to a lack of sustainable performance, indicating ongoing segment instability and potential membership attrition. Underlying medical cost trends continue to outpace program funding across the industry, particularly in Medicare Advantage, necessitating a prudent view on future profitability. Elevated cost drivers, including behavioral health, specialty pharmacy, outpatient surgery, and emergency department utilization, persist across various lines of business. The Individual ACA market is still developing, with a shift towards bronze plans impacting premium yield and risk adjustment, requiring careful management. Furthermore, increasing regulatory complexity around data privacy and algorithmic accountability could slow AI deployment and increase compliance costs.
- Bull Case
- Elevance Health is poised for long-term growth, driven by strategic, one-time investments in AI-enabled capabilities for medical cost management, clinical intervention, and improved provider connectivity. These investments, funded by a non-recurring benefit, are expected to enhance operational efficiency and leverage the company's proprietary data. The diversified portfolio is performing well, with Medicare Advantage showing improved results from deliberate repositioning and the Commercial segment experiencing strong demand and client win-backs for its integrated offerings. Carelon, with its AI-enabled solutions and value-based care models like CareBridge, is becoming a significant driver of enterprise growth. Management has raised its 2026 adjusted diluted EPS guidance to at least $27 and remains confident in achieving at least 12% adjusted EPS growth in 2027, anticipating 2026 to be the trough year for Medicaid margins with subsequent improvements.
- More Compelling & Why
- Bear. Despite raised guidance, the stock experienced a significant post-earnings decline of 8.5% to 12.1%, indicating market skepticism. The P/E ratio (TTM) of approximately 18.09 is near its 10-year median, suggesting the valuation isn't cheap enough to absorb the persistent Medicaid challenges, including the -1.75% operating margin outlook for 2026 and planned market exits. This, coupled with elevated underlying medical cost trends, is the strongest bear argument. My view would flip if Medicaid margins show sustained sequential improvement significantly above current expectations, and the AI investments demonstrably mitigate overall medical cost trends, leading to a re-rating of the stock.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Medicare Advantage (MA) Operating Margin Achievement | MA is a key growth area. Achieving the targeted 2% operating margin for 2026 demonstrates effective portfolio repositioning and disciplined bid strategy, supporting sustainable performance. | Elevance Health's reported full-year 2026 Medicare Advantage operating margin. | Bullish if full-year 2026 MA operating margin is at least 2%, confirming the success of strategic actions. | Elevance Health's Q4 2026 earnings release and conference call transcript (expected early 2027). | CMS (Centers for Medicare & Medicaid Services) announcements on MA program changes or performance data. | YipitData: Medicare Advantage enrollment trends for ELV and competitors. |
| Realization of Benefits from 2026 One-Time Strategic Investments | These investments, funded by a non-recurring benefit, are designed to accelerate long-term capabilities in AI, medical cost management, and member experience, directly supporting the 2027 EPS growth target. | Management commentary in future earnings calls (Q4 2026, Q1 2027) on the progress and initial impacts of these investments on medical cost trend, operational efficiency, and member engagement. | Bullish if management provides concrete examples of improved medical cost trend detection (e.g., 'months to days'), enhanced operational efficiency, or positive member experience metrics directly attributable to these investments, supporting the 12% adjusted EPS growth target for 2027. | Elevance Health's Q4 2026 and Q1 2027 earnings releases and conference call transcripts. | Company press releases detailing new AI-enabled product features or partnerships. | Thinknum: AI Product & Engineering Job Postings for Elevance Health (growth/specialization). |
| Medicaid Operating Margin Trajectory | Medicaid is a significant part of ELV's portfolio. Improvement from the 2026 trough indicates successful cost management and rate alignment, crucial for overall profitability and confidence in 2027 EPS growth. | Elevance Health's reported Q3 and Q4 2026 Medicaid operating margin, and management commentary on the pace of improvement and specific drivers (rate updates, care management actions). | Bullish if Q3/Q4 2026 Medicaid operating margin shows sequential improvement from Q2's -1.75% outlook, confirming 2026 as the trough year. | Elevance Health's Q3 and Q4 2026 earnings releases and conference call transcripts. | State Medicaid program updates (rate changes, policy shifts) from state government health department websites. | AlphaSense/Tegus: Mentions of 'Medicaid margin improvement' or 'Medicaid trend' in competitor earnings calls. |
| Execution of Medicaid Market Exits | Disciplined market exits are crucial for improving the long-term sustainability and profitability of the Medicaid portfolio, even if it impacts membership and revenue in the short term. | Announcements of additional Medicaid market exits over the next 12-18 months, including the number of states and estimated revenue/membership impact. | Bullish if exits are executed as planned, focusing on markets without a clear path to sustainable performance and aligning with strategic fit and return on capital criteria. | Elevance Health's future earnings releases, conference call transcripts, and potentially state government health department announcements. | State government news releases regarding changes in Medicaid managed care contracts. | AlphaSense/Tegus: Mentions of 'Medicaid market exit' or 'portfolio optimization' in ELV and competitor transcripts. |
| Commercial Group 2027 Selling Season Outcomes | Strong performance in the commercial selling season, indicated by high demand and client wins/returns, signals continued growth and market share gains in a competitive segment. | Management commentary on 2027 commercial group membership growth, persistency rates, and new client wins in Q3 and Q4 2026 earnings calls. | Bullish if management reports continued strong demand, high persistency rates, and significant new client acquisitions (including win-backs) for the 2027 selling season, indicating sustained momentum. | Elevance Health's Q3 and Q4 2026 earnings releases and conference call transcripts. | Industry reports on employer-sponsored health plan market trends. | YipitData: Commercial health plan enrollment data for ELV and key competitors. |
Key Reported Metrics, Reratings Triggers & ResultsCarelon is a key strategic asset, leveraging AI-enabled capabilities and value-based solutions. Its growth demonstrates the success of these investments and its
| Key reported metrics | ||
|---|---|---|
| Metric | Last period | Why it matters |
| Carelon Operating Revenue Growth | 6% | Carelon is a key strategic asset, leveraging AI-enabled capabilities and value-based solutions. Its growth demonstrates the success of these investments and its increasing contribution as a durable driver of enterprise growth. |
| Medicaid Operating Margin | -1.75% | Medicaid is a dynamic and challenging segment for Elevance Health. Its margin performance, especially given the 'trough year' expectation and planned market exits, is critical for understanding the company's risk management and future profitability. |
| Adjusted Diluted Earnings Per Share Growth | -15.7% | This is the primary indicator of overall profitability and management's execution. Raised guidance signals confidence, and achieving 2027 growth targets is crucial for investor sentiment regarding the company's long-term financial health. |
Key QuestionsGiven the stated expectation of 2026 being the trough year for Medicaid margins and planned market exits, will Elevance Health demonstrate tangible sequential i
Given the stated expectation of 2026 being the trough year for Medicaid margins and planned market exits, will Elevance Health demonstrate tangible sequential improvement in its Medicaid operating margin in the second half of 2026, and provide clear progress on its strategic market exits, validating its path to sustainable performance?
- Question 2
Can Elevance Health provide concrete evidence in the coming quarters that its one-time 2026 investments in AI-enabled medical cost management, member engagement, and provider connectivity are generating the anticipated operational leverage and contributing to the confidence in achieving at least 12% adjusted EPS growth in 2027?
- Question 3
Will Elevance Health sustain the improved operating margin in Medicare Advantage, targeting at least 2% for 2026, and continue to demonstrate strong demand and client wins in its Commercial Group business for the 2027 selling season, confirming the broad-based strength of its portfolio?
Earnings Transcript Summary
· 2026Q2 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. **Disciplined management of healthcare costs and execution:** Management emphasized disciplined execution and actions to manage healthcare costs more effectively across the enterprise, including earlier detection of medical cost trends, more precise clinical intervention, payment integrity, network management, and operational efficiency. 2. **Strategic investments in capabilities for long-term performance:** The company is accelerating one-time investments, funded by a non-recurring benefit, into capabilities such as AI-enabled tools, Sydney Health, Concierge Care, Health OS, and Carelon's value-based solutions. These investments aim to strengthen medical cost management, improve member experience, enhance provider connectivity, and drive long-term durability. 3. **Portfolio optimization and disciplined management of Medicaid:** Management is actively assessing and exiting Medicaid markets that do not offer a path to sustainable performance and appropriate return on capital, while remaining committed to markets where value can be delivered for states, members, and shareholders. | The overall takeaway is that Elevance Health delivered strong second-quarter results, exceeding its outlook and leading to a raised 2026 adjusted EPS guidance. The company is making strategic, one-time investments to enhance long-term capabilities and drive future performance, particularly in medical cost management and member experience. While the Medicaid business remains a focus due to its dynamic environment and ongoing portfolio optimization, management expressed confidence in the overall diversified portfolio's ability to drive at least 12% adjusted EPS growth in 2027. The tone of the call was cautiously optimistic and prudent, balancing strong performance and future growth prospects with a disciplined approach to challenging market segments. | In Q1 2026, Total Operating Revenue increased by 1.5% year-over-year. The Health Benefits segment operating revenue increased by 2.6% year-over-year, and Carelon operating revenue increased by 7.9% year-over-year. | 1. **Medicaid performance, margin trajectory, and market exits:** Analysts questioned the Medicaid business's -1.75% operating margin, the expected improvement trajectory, and the rationale/sizing of planned market exits. *Management Response:* Management stated that the Medicaid environment is dynamic but manageable. Q2 performance supports the full-year framework, with stronger-than-expected rates and aligned membership/acuity. They expect the second-half Medicaid margin to improve from Q2 due to favorable July 1st rates and continued cost management. Market exits are strategic, disciplined decisions based on long-term sustainability and fit, with 2026 viewed as the trough year for Medicaid margins. 2. **Individual ACA business performance and risk adjustment:** Analysts inquired about the favorability in the Individual ACA business, particularly regarding risk adjustment results and whether this would be carried forward. *Management Response:* Management confirmed favorable final 2025 risk adjustment results but is prudently not extrapolating this favorability into 2026. They are reestablishing much of it into the 2026 risk adjustment accrual due to the developing market, changing member mix, and shift towards bronze plans. Q2 favorability reflected pronounced seasonality and better early membership. 3. **Impact and non-recurrence of one-time investments on 2027 growth:** Analysts sought clarification on the $0.80 per share non-recurring benefit and how these one-time investments would translate into 2027 EPS growth. *Management Response:* Management clarified that the $0.80 per share non-recurring benefit is being used for one-time, accelerated investments in 2026 to build long-term, durable capabilities. These investment costs will not reoccur in 2027. They are designed to improve operating leverage and support confidence in achieving at least 12% adjusted EPS growth in 2027 off the new $26 baseline. | Total Operating Revenue increased by 0.8% year-over-year. Specific year-over-year growth percentages for individual segments (Medicaid, Medicare Advantage, Individual ACA, Commercial, Carelon) were not explicitly provided in the transcript for Q2 2026. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Elevance Health is expanding CareBridge, which generates medical savings in the mid-teens for members, into new markets. The company is also expanding Carelon's capabilities across new populations and external client relationships. Conversely, Elevance Health plans to exit additional Medicaid markets over the next 12-18 months where sustainable performance is not achievable, following a mutual agreement to exit the D.C. Medicaid market. Medicaid participation is assessed based on strategic fit, operational requirements, and the ability to generate an appropriate return on capital, particularly where there is alignment with duals and the Carelon strategy. | In the commercial market, Elevance Health's differentiated offerings are resonating with employers who are focused on affordability and experience. The company's integrated medical and pharmacy model, patient advocacy, behavioral health, and digital engagement capabilities are in strong demand. Elevance Health has seen customers who previously left for alternative payers return, indicating the quality of its assets and its ability to make healthcare more affordable and easier to navigate. | The healthcare system is facing consumer expectations for greater transparency, better connectivity, and more personalized support. The Medicaid environment remains dynamic with elevated cost drivers in behavioral health, specialty pharmacy, outpatient surgery, and emergency department utilization. The ACA market is still developing, with a meaningful shift in member mix towards bronze plans impacting premium yield and risk adjustment. Across the industry, underlying medical cost trend is still outpacing program funding, particularly in Medicare Advantage. | Elevance Health is raising its 2026 adjusted diluted earnings per share guidance to at least $27 and remains confident in achieving at least 12% adjusted EPS growth in 2027. The company expects 2026 to be the trough year for its Medicaid margin, with improvements anticipated over time due to better rate alignment and maturing care management actions. Investments in capabilities are designed to strengthen the enterprise's long-term performance, focusing on medical cost management, member engagement, provider connectivity, and Carelon's integrated solutions. | Data | The broader theme of AI adoption and its impact on various industries is evident, with Elevance Health investing in AI-enabled capabilities for medical cost management, member engagement, and provider connectivity. There's also an emerging trend of increasing regulatory complexity with US states enacting their own AI laws and data privacy regulations, which can create both challenges and defensible moats for compliant data owners. | Elevance Health delivered second quarter results ahead of our outlook. Today, we are raising our 2026 adjusted diluted earnings per share guidance to at least $27, and we remain confident in our ability to return to at least 12% adjusted EPS growth in 2027. Carelon and our AI-enabled capabilities are becoming more meaningful contributors. In Medicare Advantage, we are seeing clear evidence that the deliberate actions we took to reposition the portfolio are translating into stronger performance. Our integrated medical and pharmacy model is resonating, we're seeing strong demand for our patient advocacy, behavioral health, and digital engagement capabilities. Our pipeline came back almost just as large this year for the 2027 business as we had in 2026. | The Medicaid environment continues to be dynamic, and we're managing it with discipline. We expect to exit additional Medicaid markets over the next 12-18 months where we do not see a path to sustainable performance. Cost drivers remain elevated and concentrated in the categories we have discussed previously, including behavioral health, specialty pharmacy, outpatient surgery, and emergency department utilization. We are not assuming a material improvement in Medicaid trend in the back half of the year. We do continue to believe underlying medical cost trend is still outpacing program funding. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-07-15 | Elevance Health's Q2 2026 earnings, despite raised 2026 EPS guidance and confidence in 2027 growth, were met with a negative market reaction, with the stock falling 12.64% (vs. SPY -0.15%). Investors likely focused on the dynamic Medicaid environment, elevated cost trends, and planned market exits, overshadowing strategic AI investments and strong Commercial/Medicare Advantage performance. | Earnings Transcript | Negative | -12.64% (vs SPY: -12.49%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| ELV_db604a61 | on January 1, 2027 | 2027-01-01 | 2027-01-01 | Colorado's AI Act takes effect. | This regulatory trend impacts data owners operating across multiple US states, necessitating increased investment in legal and technical compliance, but also creating defensible moats for compliant companies like Elevance Health. | Theme | 2026-07-15 | earnings_transcript |
| ELV_a18fa88a | in August 2026 | 2026-08-01 | 2026-08-31 | EU AI Act's high-risk requirements take effect. | This regulatory development creates significant compliance challenges but also defensible moats for data owners like Elevance Health who can establish robust governance and algorithmic accountability. | Theme | 2026-07-15 | earnings_transcript |